- Drug repurposing, which involves finding new therapeutic uses for existing medications, is emerging as a vital strategy in the treatment of mitochondrial disorders, offering faster development timelines, reduced costs, and lower risks compared to de novo drug development
- The growing demand for repurposed drugs is primarily fueled by increased awareness of mitochondrial diseases, unmet clinical needs, and advancements in genomic and metabolic research enabling better disease targeting
- North America dominated the drug repurposing for mitochondrial disorders market, capturing the largest revenue share of 41.7% in 2024, driven by early adoption of precision medicine approaches, strong research infrastructure, supportive regulatory frameworks, and the presence of key players actively engaged in drug repositioning trials for mitochondrial dysfunctions, especially in the U.S.
- Asia-Pacific is expected to be the fastest-growing region in the drug repurposing for mitochondrial disorders market during the forecast period, propelled by rising healthcare expenditures, increasing diagnosis rates of rare diseases, and growing collaborations between local biotech firms and global pharmaceutical companies
- Approved Drugs segment dominated the drug repurposing for mitochondrial disorders market, accounting for the largest market share of 58.4% in 2024, primarily due to the availability of regulatory-approved therapies for managing mitochondrial symptoms, increased clinician trust, and reimbursement eligibility. These
